title: Iron chelation therapy to prevent the manifestations of aceruloplasminemia.
authors: From Università Cattolica del Sacro Cuore (F.B.), Gemelli University Hospital, Rome, Italy; and Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease (A.F.), Toronto Western Hospital-UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
authors: Francesco
authors: F
authors: Bove
authors: From Università Cattolica del Sacro Cuore (F.B.), Gemelli University Hospital, Rome, Italy; and Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease (A.F.), Toronto Western Hospital-UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada. alfonso.fasano@uhn.ca.
authors: Alfonso
authors: A
authors: Fasano
mesh_terms: D002570:Ceruloplasmin / Q000172:deficiency*; D015913:Chelation Therapy / Q000379:methods*; D000077543:Deferiprone; D005260:Female; D006801:Humans; D007501:Iron; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019189:Iron Metabolism Disorders / Q000175:diagnosis / Q000517:prevention & control*; D008875:Middle Aged; D019636:Neurodegenerative Diseases / Q000175:diagnosis / Q000517:prevention & control*; D011728:Pyridones / Q000627:therapeutic use*
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D002570:Ceruloplasmin